2023 GEM Kick-off Meeting

Is there a turnover threshold for a market to be classified as a candidate for GEM?

There is no exact turnover threshold for a market to be classified as a candidate for GEM. More importantly, we look at the operational and geographic synergies.

Dimitris, what is a personal goal of yours for 2023?

Successfully integrate the new GEM markets.

Is the acceleration in Q4 and Dec-22 a seasonal effect? i.e., was the trend similar in end of 2021?

Q4 is positively impacted by phasing for SX franchise (this is the strongest quarter historically, especially for Equipment) while for VC the sales peak due to seasonality is reached in Q2/Q3; what is really impressive in Q4 performance is the “velocity exit” of December month: usually December is not the strongest month of Q4 (also because due to Christmas being a “short” month) and APL legal entity, due to the complexity of year end activities, usually perform an “early cut off” (stopping delivering products before Christmas). Therefore, this exceptionally strong performance of December is demonstrating our GEM positive momentum and is the “reason to believe” that 2023 sales TGT, despite being not easy, looks realistically achievable!

We didn’t hear any news about refractive equipment in GEM, can you please share the updates? How many machines we sold in 2022 and where are we standing as market share?

During our kick-off Meeting we covered the 3 main SX priorities. Nevertheless, Refractive is also an important component of our business especially, in some GEM markets. In 2022 we sold 29 units of EX500 and 2 units FS200. This is almost similar to PY level. The main contributor is MEA cluster representing almost 50% of the 2022 sales followed by CSEE and NA. The market shares vary a lot from one GEM market to another. In International, The Excimer market share is 40%, and in GEM as a total, we have bigger MS, around 55%. (main competitors are Schwind and J&J Vision).

Regarding innovation, R&D are working on an improved version of “InnovEyes”, name to be confirmed. Expected to be approved for 2024. The advantage is that we will have solid clinical data at the time of launch in International Markets.

Previously, Alcon had some development programs such as the M1. Do we have a plan to implement something similar again?

We have launched various Global leadership Development courses in 2022, which include courses on leading self or leading others. We have already planned dates for 2023 and are in the process of working with Leaders to nominate associates for these trainings. More information can be found on this PAGE